RNA, U4atac small nuclear 15, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4ATAC15P profile across patient tissues and cancer cell-line models. RNU4ATAC15P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU4ATAC15P is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, RNU4ATAC15P RNA expression shows 5,886 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, KIRP, and STAD as cancer lineages where RNU4ATAC15P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4ATAC15P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4ATAC15P survival associations across molecular data types. RNU4ATAC15P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4ATAC15P RNA expression–survival associations across cancer types. High RNU4ATAC15P expression shows unfavorable associations in MESO, UVM, PAAD and THYM, but favorable associations in STAD and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNU4ATAC15P RNA expression.
This table summarizes RNU4ATAC15P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4ATAC15P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4ATAC15P shows lower tumor expression in KIRP and KIRC. The KIRP box plot shows higher RNU4ATAC15P RNA expression in normal versus tumor tissue (log2 FC = −0.080, t-test p = .027).
This table shows molecular features associated with RNU4ATAC15P in patient tissues and cancer cell lines. In patient samples, RNU4ATAC15P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
